Literature DB >> 401003

Symptomatic volunteers in multicenter drug trials.

L Covi1, R S Lipman, D M McNair, T Czerlinsky.   

Abstract

1. Symptomatic volunteers were recruited at two collaborating institutions for anti-anxiety and antidepressant drug trials. Advertisements were placed for volunteers with significant symptoms of anxiety, depression, or both, and who were not currently in treatment. 2. It was possible to recruit adequate numbers of volunteers who met the numerous criteria for severity of distress; and who were not ruled out by various exclusion criteria, such as medical contraindications, etc. 3. Acceptable homogeneity across the samples at the collaborating institutions was found for demographic characteristics, level of distress, duration of symptoms, etc. 4. Attrition rates for these volunteers were lower than for the typical anxiolytic and antidepressant trials using outpatients. 5. Symptomatic volunteers appear to present a feasible alternative to the increasingly diminishing pool of outpatients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 401003     DOI: 10.1016/0364-7722(79)90006-7

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol        ISSN: 0364-7722


  13 in total

Review 1.  Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity.

Authors:  Mark Zimmerman; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian; Heather L Clark
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

2.  Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.

Authors:  Shlomo Brook; Jeorg Walden; Isma Benattia; Cynthia O Siu; Steven J Romano
Journal:  Psychopharmacology (Berl)       Date:  2005-01-14       Impact factor: 4.530

3.  Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder.

Authors:  M Ansseau; J P Olié; R von Frenckell; G Jourdain; B Stehle; P Guillet
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder.

Authors:  Y Lecrubier; A J Puech; A Azcona; P E Bailey; X Lataste
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Amoxapine and amitriptyline. I. Relative speed of antidepressant action.

Authors:  D M McNair; R J Kahn; L M Frankenthaler; L L Faldetta
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Psychometric evaluation of a visual analog scale for the assessment of anxiety.

Authors:  Valerie S L Williams; Robert J Morlock; Douglas Feltner
Journal:  Health Qual Life Outcomes       Date:  2010-06-08       Impact factor: 3.186

7.  Validation of the repetitive and restricted behaviour scale in autism spectrum disorders.

Authors:  Yannig Bourreau; Sylvie Roux; Marie Gomot; Frédérique Bonnet-Brilhault; Catherine Barthélémy
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-05-19       Impact factor: 4.785

8.  The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.

Authors:  Mark Zimmerman; Carolina Guzman Holst; Heather L Clark; Matthew Multach; Emily Walsh; Lia K Rosenstein; Douglas Gazarian
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

9.  Controlled comparison of milnacipran and fluoxetine in major depression.

Authors:  M Ansseau; P Papart; B Troisfontaines; F Bartholomé; M Bataille; G Charles; M Schittecatte; P Darimont; J M Devoitille; J De Wilde
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

10.  Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics.

Authors:  N Broutet; M Plebani; C Sakarovitch; P Sipponen; F Mégraud
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.